This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through September 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
Is Novo Nordisk Stock a Sell Despite its 10% Price Rally in a Month?
by Ahan Chakraborty
NVO's 10% stock price rally masks deeper challenges as competition, restructuring and slower growth weigh on its outlook.
NVONegative Net Change LLYPositive Net Change AMGNPositive Net Change VKTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
BDTX Stock Hits 52 Week High: Is There More Room for Growth?
by Ekta Bagri
Black Diamonds shares surge 86.4% in 2025 as strong silevertinib data and rising estimates fuel optimism for further gains.
AZNNegative Net Change JNJPositive Net Change BDTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Regeneron Gets FDA Nod for Label Expansion of Oncology Drug Libtayo
by Zacks Equity Research
REGN secures FDA approval to expand Libtayo's label for high-risk skin cancer, boosting its oncology momentum amid Eylea sales pressure.
REGNPositive Net Change SNYPositive Net Change RHHBYPositive Net Change
biotechnology biotechs medical
Bayer Reports Positive Data on Cell Therapy for Parkinson's Disease
by Zacks Equity Research
BAYRY's subsidiary BlueRock reports 36-month data showing its Parkinson's therapy bemdaneprocel remains safe and effective in easing motor symptoms.
JNJPositive Net Change BAYRYPositive Net Change FOLDPositive Net Change SPROPositive Net Change
biotechnology biotechs medical pharmaceuticals
KALA Stock Crashes 88% in a Month Following Eye Disorder Study Failure
by Zacks Equity Research
KALA BIO stock plunges 88% after its KPI-012 eye disorder study fails to meet goals, forcing the company to scrap its pipeline and explore strategic options.
KALANegative Net Change ALLOPositive Net Change AKROPositive Net Change CMMBNegative Net Change
biotechnology biotechs medical pharmaceuticals
Can BMYs Neuroscience Portfolio Help to Diversify Its Business?
by Zacks Equity Research
Bristol Myers gains FDA Fast Track status for its Alzheimer's antibody BMS-986446 as Cobenfy drives early sales and pipeline momentum.
BIIBNegative Net Change BMYPositive Net Change LLYPositive Net Change
biotechnology biotechs medical pharmaceuticals
SKYE Stock Plunges 60% as Obesity Candidate Misses Key Phase II Goal
by Zacks Equity Research
Skye Bioscience stock nosedives 60% after its investigational obesity candidate, nimacimab, fails to meet the key goal in a mid-stage study.
NVONegative Net Change FOLDPositive Net Change AVDLNegative Net Change SKYENo Net Change
biotechnology biotechs medical pharmaceuticals
Will CorMedix's DefenCath Edge Last If Bigger Heparin Rivals Close In?
by Ahan Chakraborty
CRMD's DefenCath gives the company a first-mover edge in CRBSI prevention, but looming heparin giants test how long its lead can last.
PFENegative Net Change AMPHNegative Net Change CRMDNegative Net Change
biotechnology biotechs medical pharmaceuticals
Gilead Resolves Patent Litigations for HIV Treatment Biktarvy
by Zacks Equity Research
Gilead's settlement on Biktarvy patents delays generic entry until 2036, boosting investor confidence.
GSKPositive Net Change MRKPositive Net Change GILDNegative Net Change BAYRYPositive Net Change
biotechnology biotechs medical pharmaceuticals
Roche Wins FDA Nod for Label Expansion of Tecentriq in Lung Cancer
by Zacks Equity Research
Roche gains FDA approval for Tecentriqs expanded label, marking the first combo maintenance therapy for extensive-stage small cell lung cancer.
RHHBYPositive Net Change JAZZPositive Net Change ETNBPositive Net Change
biotechnology biotechs medical pharmaceuticals
GMAB Stock Soars 21.9% in a Month Following MRUS Acquisition Deal
by Zacks Equity Research
Genmab stock surges 21.9% after striking an $8 billion deal to buy Merus, adding a late-stage cancer treatment candidate to its proprietary oncology pipeline.
CRMDNegative Net Change MRUSPositive Net Change KNSANegative Net Change GMABNegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Best Momentum Stock to Buy for October 3rd
by Zacks Equity Research
GFI, GMAB and AEG made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 3, 2025.
AEGPositive Net Change GFINegative Net Change GMABNegative Net Change
biotechnology finance gold
Can Novo Nordisk's Restructuring Program Drive its Return to Growth?
by Ahan Chakraborty
NVO is cutting 9,000 jobs, targeting DKK 8 billion in savings, and shifting focus to obesity and diabetes R&D to regain growth momentum.
BMYPositive Net Change NVONegative Net Change MRKPositive Net Change
biotechnology biotechs medical pharmaceuticals
Can CYTK Clinch a Potential FDA Nod for Its Cardiovascular Drug?
by Zacks Equity Research
Cytokinetics' aficamten shows superiority over metoprolol in late-stage oHCM trial, boosting investor confidence despite FDA delay.
BMYPositive Net Change BAYRYPositive Net Change CYTKNegative Net Change
biotechnology biotechs medical pharmaceuticals
Can Alnylam's Broader Portfolio Ease Its Dependence on Amvuttra?
by Ahan Chakraborty
ALNY's portfolio of rare disease and cardiovascular drugs is boosting revenues and reducing reliance on Amvuttra.
ALNYPositive Net Change NVSNegative Net Change PFENegative Net Change BBIONegative Net Change
biotechnology biotechs medical pharmaceuticals
Kymera Overcomes Sanofi Deal Update, Marches Ahead With Pipeline
by Zacks Equity Research
Kymera advances its protein degradation pipeline with new Sanofi and Gilead deals, milestone payouts, and promising trial updates.
SNYPositive Net Change GILDNegative Net Change KYMRPositive Net Change
biotechnology biotechs medical pharmaceuticals
Can NVO Maintain Obesity Leadership With Next-Generation Candidates?
by Ahan Chakraborty
Novo Nordisk is expanding beyond Wegovy and Ozempic with next-generation obesity candidates and strategic deals to defend its market lead.
NVONegative Net Change LLYPositive Net Change VKTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Krystal Biotech's Heavy Reliance on Vyjuvek: Growth Driver or Risk Factor?
by Zacks Equity Research
KRYS gains momentum with Vyjuvek's expanded FDA label and global approvals, while advancing a pipeline led by oncology candidate KB707.
BMYPositive Net Change MRKPositive Net Change ABEOPositive Net Change KRYSPositive Net Change
biotechnology biotechs gene-therapy medical pharmaceuticals
FDA Approves Label Extension of REGN's Cholesterol Drug Evkeeza
by Zacks Equity Research
Regeneron wins FDA approval to extend Evkeeza use in children as young as one with severe familial hypercholesterolemia.
REGNPositive Net Change SNYPositive Net Change RHHBYPositive Net Change RAREPositive Net Change
biotechnology biotechs medical pharmaceuticals
CDTX Stock Soars 218% YTD on Positive Updates From Influenza Program
by Zacks Equity Research
Cidara Therapeutics' shares surge 218% this year after its flu candidate CD388 hits key mid-stage study goals and advances into pivotal testing.
CRMDNegative Net Change CDTXPositive Net Change KNSANegative Net Change PHARPositive Net Change
biotechnology biotechs medical pharmaceuticals
MRK vs. BMY: Which Pharma Stock Is the Smarter Pick Now?
by Ekta Bagri
Merck and Bristol Myers face diverging growth paths, with Keytruda driving MRK's momentum and BMY navigating generic headwinds.
BMYPositive Net Change MRKPositive Net Change
biotechnology biotechs cancer medical pharmaceuticals
Will BDTX's EGFR Inhibitor Bring a Paradigm Shift in NSCLC Treatment?
by Ekta Bagri
Black Diamond's silevertinib aims to challenge Tagrisso, offering broad EGFR mutation coverage, as key trial results are expected in late 2025.
AZNNegative Net Change JNJPositive Net Change BDTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
QURE Stock Skyrockets on Meeting Goals in Huntington's Disease Study
by Zacks Equity Research
uniQure N.V. shares surge nearly 248% after its gene therapy candidate, AMT-130, met key goals in a pivotal Huntington's disease study.
CRMDNegative Net Change QUREPositive Net Change KNSANegative Net Change PHARPositive Net Change
biotechnology biotechs gene-therapy genomics medical pharmaceuticals
ACAD Stock Down 10% Following Phase III Hyperphagia Study Failure
by Zacks Equity Research
Acadia Pharmaceuticals stock tumbles 10% after its phase III hyperphagia study failure, but growth remains driven by Nuplazid, Daybue and a robust pipeline.
CRMDNegative Net Change ACADNegative Net Change SLNOPositive Net Change KNSANegative Net Change
biotechnology biotechs medical pharmaceuticals
HRMY Stock Down as Fragile X Syndrome Study Fails to Meet Goal
by Zacks Equity Research
Harmony Biosciences' shares plunge after ZYN002 failed in Fragile X, but Wakix sales and new epilepsy assets keep its pipeline moving forward.
HALONegative Net Change ANIPNegative Net Change HRMYPositive Net Change
biotechnology biotechs medical pharmaceuticals